XX
XXA1.F Axcelis Technologies Inc
- Market cap
- EUR 2.96B
- P/E
- 33.2x
- P/B
- 3.05x
- ROE
- 8.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is XXA1.F undervalued?
Graham numberXXA1.F trades 112.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Axcelis Technologies Inc fundamental analysis
No fundamental analysis for Axcelis Technologies Inc yet.
Axcelis Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Axcelis Technologies Inc
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. The company provides high energy, high current, and medium current implanters for various application requirements. It also offers aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer tra…
Full company profileAxcelis Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Axcelis Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 267M | 411M | 443M | 343M | 475M | 662M | 920M | 1.13B | 1.02B | 839M | 869M |
| Gross Profit | 99.6M | 150M | 180M | 144M | 199M | 286M | 402M | 491M | 455M | 377M | 359M |
| Operating Income | 16.9M | 47.8M | 60.0M | 24.2M | 58.0M | 127M | 212M | 266M | 211M | 119M | 74.1M |
| EBITDA | - | 54.0M | 65.6M | 34.0M | 71.0M | 125M | 210M | 297M | 252M | 161M | 120M |
| Net Income | 11.0M | 127M | 45.9M | 17.0M | 50.0M | 98.7M | 183M | 246M | 201M | 120M | 93.7M |
| EPS | - | 3.96 | 1.41 | 0.52 | 1.49 | 2.95 | 5.59 | 7.53 | 6.21 | 3.91 | 3.03 |
| Balance Sheet | |||||||||||
| Total Assets | 302M | 488M | 548M | 548M | 625M | 753M | 1.01B | 1.28B | 1.35B | 1.36B | 1.48B |
| Total Liabilities | 101M | 135M | 140M | 129M | 143M | 214M | 346M | 417M | 336M | 327M | 364M |
| Shareholders' Equity | 201M | 354M | 408M | 419M | 482M | 539M | 667M | 865M | 1.01B | 1.03B | 1.11B |
| Cash & Short-term Investments | 70.8M | 133M | 178M | 140M | 203M | 295M | 186M | 167M | 124M | 145M | 191M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.79M | 56.3M | 47.0M | -13.6M | 69.7M | 150M | 216M | 214M | 141M | 118M | 102M |
| Capital Expenditure | 2.51M | 7.29M | 4.72M | 12.0M | 7.43M | 8.72M | 10.7M | 14.3M | 12.2M | 11.3M | 10.5M |
| Free Cash Flow | - | 49.0M | 42.3M | -25.6M | 62.3M | 141M | 205M | 199M | 129M | 107M | 91.8M |
| Ratios | |||||||||||
| ROE | 5.5% | 35.9% | 11.2% | 4.1% | 10.4% | 18.3% | 27.4% | 28.5% | 19.8% | 11.6% | 8.4% |
| ROA | 3.6% | 26.0% | 8.4% | 3.1% | 8.0% | 13.1% | 18.1% | 19.2% | 14.9% | 8.8% | 6.3% |
| Net Profit Margin | 4.1% | 30.9% | 10.4% | 5.0% | 10.5% | 14.9% | 19.9% | 21.8% | 19.7% | 14.3% | 10.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Axcelis Technologies Inc dividends
Axcelis Technologies Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Jul 1, 2016.
Who owns Axcelis Technologies Inc
- Insiders 0.68%
- Institutions 99.32%
- Public & others 0.00%
- Shares outstanding 30.9M
- Free float 30.7M
Axcelis Technologies Inc company profile
- Company name
- Axcelis Technologies Inc
- Ticker
- XXA1.F
- Exchange
- Frankfurt Exchange
- Sector
- Technology
- Industry
- Semiconductors & Semiconductor Equipment
- Employees
- 1,465
- Fiscal year end
- December
- Address
- 108 Cherry Hill Drive, Beverly, MA, United States, 01915-1088
- Phone
- 978 787 4000
- Website
- axcelis.com
About Axcelis Technologies Inc
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. The company provides high energy, high current, and medium current implanters for various application requirements. It also offers aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. The company sells its equipment and services to semiconductor chip manufacturers through its direct sales force. Axcelis Technologies, Inc. was founded in 1978 and is headquartered in Beverly, Massachusetts.
Axcelis Technologies Inc management
5- Dr. Russell J. Low Ph.D.CEO, President & Director · born 1971
- Mr. Gregory F. Redinbo Ph.D.Chief Strategy Officer & Executive VP of Strategic Marketing & Technology · born 1965
- Ms. Eileen J. Evans Esq.Executive VP of Human Resources and Legal, General Counsel & Secretary · born 1968
- Mr. Gerald M. BlumenstockExecutive VP & GM of Implant Business Unit (IBU) · born 1969
- Dr. Christopher J. Tatnall Ph.D.Executive Vice President of Global Customer Operations · born 1973